US ▾
IPIPGP

IPG Photonics (IPGP) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Aug 4, 2026

Source: earnings call transcript

Executive summary

IPG Photonics Q2 FY26 — Strong Revenue Growth and Strategic Acquisitions Drive Performance

IPG Photonics delivered a strong second quarter, exceeding revenue and adjusted profitability expectations, driven by robust demand in industrial applications and sequential improvement in advanced solutions. The company is actively executing on strategic growth initiatives, including the acquisition of Lumibird Medical to expand into higher-margin medical markets and advancing its directed energy defense system. Management remains confident in long-term demand trends and continued margin expansion through cost optimization and operational efficiency.

Highlights

5

  • Total revenue of $279 million, up 11% year-over-year, marking the third consecutive quarter of double-digit growth.

  • Adjusted gross margin of 40.7% and adjusted EPS of $0.58, both above the top end of guidance.

  • Book-to-bill remained above 1 for the third consecutive quarter, indicating sustained demand.

  • Industrial Solutions revenue increased 16% year-over-year, led by battery manufacturing, cleaning, and additive manufacturing.

  • Advanced Solutions revenue improved 10% quarter-over-quarter, driven by strong growth in semiconductor applications.

Concerns

4

  • North American revenue decreased 2% year-over-year due to lower sales in cutting, defense, and medical applications.

  • Advanced Solutions revenue decreased 9% compared to last year, despite sequential improvement, due to lower micromachining and defense revenue.

  • Ongoing impact from tariffs of about 150 basis points expected to affect Q3 gross margin.

  • Manufacturing cost absorption remains below target levels, despite positive benefits from lower inventory provisions and product costs.

Guidance & targets

CategoryTargetConfidence
Q3 FY26 Revenue
$265 million to $295 million
high materiality
High
Q3 FY26 Adjusted Gross Margin
37.5% to 40.5%
high materiality
High
Q3 FY26 Adjusted Operating Expenses
$92 million to $95 million
medium materiality
High
Q3 FY26 Adjusted EPS
$0.30 to $0.60
high materiality
High
Q3 FY26 Adjusted EBITDA
$35 million to $51 million
medium materiality
High
FY26 Capital Expenditures
$90 million to $100 million
medium materiality
High
Medical Business Growth
more than double
medium materiality
High
Operating Expenses
modestly increase
low materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Industrial Solutions
Growth driven by welding, marking, cleaning, and additive manufacturing. Sequential growth primarily due to strength in welding and cleaning.
—16%4%—
Advanced Solutions
Year-over-year decrease due to lower revenue in micromachining and defense, offset by semiconductor growth. Sequential improvement driven by semiconductor and micromachining applications.
—-9%10%—
North America
Year-over-year decrease due to lower revenue in cutting, defense, and medical applications. Sequential increase due to increased marketing and defense sales.
—-2%1%—
Europe
Growth driven by increased sales in cleaning and additive manufacturing, partially offset by a decrease in cutting.
—5%1%—
Asia
Growth driven by strong welding applications, benefiting from higher demand in battery manufacturing.
—19%8%—

Orderbook & backlog

Book-to-bill ratio above 1 Q2 FY26

remained above 1

Third consecutive quarter above 1, indicating sustained demand.

Medical bookings and backlog strong Q2 FY26

Expected to drive increased shipments in the second half of the year.

Product announcements

ProductTypeDetails
Latest generation of lasers with proprietary beam shaping capabilitieslaunch
Medical product approvals and introductionsroadmap

Deals & partnerships

Lumibird Medical Acquisition of a global leader in diagnostic and treatment systems for ophthalmology.

Accelerates IPG's strategic evolution by expanding Advanced Solutions into attractive, higher-margin medical markets, strengthening business mix quality, and creating a scaled medical laser platform.

Capital programs

Major fiber manufacturing facility in Germany underway

Investments in this facility are included in the FY26 CapEx outlook of $90 million to $100 million.

Risks & headwinds

Geopolitical environment and higher oil prices ongoing

impact in Europe

Tariff impact on gross margin Q3 FY26

150 basis points

Mitigation:Factored into Q3 gross margin guidance.

Manufacturing cost absorption medium term

below target

Mitigation:Several initiatives are underway to drive manufacturing efficiency and improve absorption.

What to watch in Q3 FY26

Medical business growth

next quarter and beyond
Current 7% to 8% of total revenue
Target progress towards doubling in 2-3 years

Why it matters

Medical is a higher-margin market, and its growth trajectory, especially with the Lumibird acquisition, is key to business mix quality and profitability.

We have very strong demand and backlog in medical, and we're confident that we're going to have another good year continue to -- we're continuing to advance in the innovation road map there with new product approvals and introductions that are planned in 2026 and 2027. And I talked about those, of course, Jim, we talked about the fact that we launched a key new product at the end of last year, we picked up a new key customer the fact that we have both systems as well as the disposable fibers. So those are all moving strongly and as I've talked about in the past, we expect to more than double the business over the next 2 to 3 years.

Find out whether IPGP delivers this. Inve re-checks your case every morning.

Q&A highlights

Given three consecutive quarters of book-to-bill above 1, how does the Q3 revenue guidance, which is roughly flat at the midpoint, relate to the building of shippable backlog and future quarters?

Management reiterated strong double-digit year-over-year growth for three quarters and a book-to-bill above 1, indicating encouraging signs across the business. They highlighted positive progress in Industrial Solutions with differentiated offerings and stable, expansive global PMIs, alongside positive momentum in Advanced Solutions.

“So just to step back for a second, of course, as you mentioned, we're seeing double-digit growth year-over-year, and this is the third quarter in a row for that. Book-to-bill, again, was strong, it was above 1 for the third quarter in a row. And we're really seeing encouraging signs across the business.”

asked by Ruben Roy · answered by Mark Gitin

2 min read 7 chapters

Detailed narrative

Strategic Growth Initiatives and Operational Transformation

IPG Photonics is pursuing two strategic growth initiatives: strengthening leadership in industrial solutions and expanding into attractive advanced solutions markets. The company is streamlining operations and accelerating product development through its 'One IPG operating model' to maximize growth and profit opportunities. This transformation aims to improve performance and consistency across the business, positioning IPG for above-market growth and margin expansion.

Industrial Solutions Strength and Battery Manufacturing

Revenue growth in Industrial Solutions was primarily driven by welding applications, particularly in battery manufacturing for electric vehicles and stationary storage. The company's unique adjustable mode beam lasers, advanced beam delivery, and real-time process monitoring enable unmatched welding speed and quality, leading to recent wins with major global automotive manufacturers. Demand for high-capacity batteries, supported by data centers and renewables, continues to drive strong bookings and pull in this area.

Advanced Solutions Progress and Semiconductor Growth

Advanced Solutions saw sequential improvement, led by strong growth in semiconductor applications. IPG is winning new business with large semiconductor equipment manufacturers for lithography, metrology, and inspection solutions, leveraging differentiated value and performance advantages. This growth is linked to accelerated AI-related demand for GPUs and high-bandwidth memory chips, increasing IPG's exposure to this high-growth market.

Lumibird Medical Acquisition

IPG Photonics entered into a binding offer to acquire Lumibird Medical, a global leader in ophthalmology diagnostic and treatment systems. This acquisition is expected to accelerate IPG's strategic evolution by expanding Advanced Solutions into higher-margin medical markets, improve profitability, and create a scaled medical laser platform. The deal, expected to close in Q4 2026, will increase IPG's addressable medical market by approximately $1 billion.

CROSSBOW Defense System Development

The company began shipping Lockheed Martin's order for the CROSSBOW directed energy defense system and expects more units to ship in Q3. Recent successful tests at White Sands missile range demonstrated CROSSBOW's capabilities in harsh environments and cooperative engagement tactics. Management remains optimistic about the emerging directed energy market, believing CROSSBOW's compelling cost-to-exchange ratio provides an effective solution against drone threats for both military and civilian infrastructure.

Gross Margin Improvement Initiatives

IPG is focused on driving gross margin improvements through several initiatives, including reducing product costs by moving to higher-power optical components like diodes. The company is also optimizing pricing in areas of strong differentiation and driving manufacturing efficiency to improve absorption and utilization. These efforts, coupled with increasing business scale, are expected to lead to continued gross margin expansion into 2027.

China Market Dynamics and Additive Manufacturing

China remains a significant industrial market for IPG, contributing 34% of revenue. The company is gaining share due to differentiated solutions, particularly in battery welding and additive manufacturing, winning against both local and Western competitors. In additive manufacturing, new lasers with specialized mode qualities have improved throughput by 1.5 to 2 times, reducing cost per part and expanding market applications from aerospace to medical and consumer devices. Pricing power is maintained in these differentiated areas.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.